【Cell】以彼之道还施彼身!线粒体“斗转星移”增强T细胞免疫治疗,为增强癌症免疫治疗带来新希望!

文摘   2024-09-17 22:00   上海  


Summary

Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria toT cells, overcoming these limitations. We found that bone marrow stromal cells establish nanotubular con-nections with T cells and leverage these intercellular highways to transplant stromal cell mitochondria intoCD8 + T cells. Optimal mitochondrial transfer required Talin 2 on both donor and recipient cells. CD8+ T cells with donated mitochondria displayed enhanced mitochondrial respiration and spare respiratory capacity. When transferred into tumor-bearing hosts, these supercharged T cells expanded more robustly, infiltrated the tumor more efficiently, and exhibited fewer signs of exhaustion compared with T cells that did not take up mitochondria. As a result, mitochondria-boosted CD8+ T cells mediated superior antitumor responses, prolonging animal survival. These findings establish intercellular mitochondrial transfer as a prototype of organelle medicine, opening avenues to next-generation cell therapies.


线粒体的丧失和功能障碍会导致T细胞耗竭,成为成功实施T细胞免疫治疗的主要障碍。在本研究中,我们提出了一种创新平台,向T细胞提供外源线粒体,从而克服这些局限性。我们发现,骨髓基质细胞与T细胞建立纳米管连接,并利用这些细胞间通道将基质细胞的线粒体移植到CD8+ T细胞中。线粒体的最佳转移需要供体细胞和受体细胞上都具备Talin 2。获得线粒体的CD8+ T细胞显示出增强的线粒体呼吸和备用呼吸能力。当这些“超级充能”的T细胞被转移至肿瘤宿主后,它们能够更强劲地扩增,更高效地渗透肿瘤,并且与未获得线粒体的T细胞相比,表现出更少的耗竭迹象。因此,获得线粒体增强的CD8+ T细胞能够介导更卓越的抗肿瘤反应,延长动物的生存期。这些发现将细胞间线粒体转移确立为细胞器医学的原型,为下一代细胞疗法开启了新途径。



参考文献

Baldwin JG, Heuser-Loy C, Saha T, Schelker RC, Slavkovic-Lukic D, Strieder N, Hernandez-Lopez I, Rana N, Barden M, Mastrogiovanni F, Martín-Santos A, Raimondi A, Brohawn P, Higgs BW, Gebhard C, Kapoor V, Telford WG, Gautam S, Xydia M, Beckhove P, Frischholz S, Schober K, Kontarakis Z, Corn JE, Iannacone M, Inverso D, Rehli M, Fioravanti J, Sengupta S, Gattinoni L. Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. Cell. 2024 Sep 12:S0092-8674(24)00956-5. doi: 10.1016/j.cell.2024.08.029.

肿瘤免疫前沿
关注肿瘤免疫治疗研究,传递肿瘤免疫最新研究进展!
 最新文章